BTM-1086
						    			         
			    					
				目录号 : GC32039
	BTM-1086是一种有效的抗溃疡和胃分泌抑制剂。
     
    
Cas No.:72293-17-5
Sample solution is provided at 25 µL, 10mM.
BTM-1086 is a potent anti-ulcer and gastric secretory inhibiting agent.
Functional and binding experiments shows that the (-) enantiomer (BTM-1086) has a high affinity (pKi=8.31-9.15) for the three muscarinic receptor subtypes in guinea-pig cortex (M1), heart (M2) and salivary glands (M3)[1].
BTM-1086 prevents the development of ulcer at a dose of 0.1 to 1 mg/kg, p.o., but only weakly inhibits the histamine induced gastric ulcer. The inhibitory activities of BTM-1086 are significantly higher than those of atropine sulfate. In the healing experiment with the acetic acid-induced stomach ulcer, BTM-1086 (1 mg/kg/day , p.o., x14) shows a significant healing effect, which is higher than that of propantheline bromide . BTM-1086 at a dose of 0.2 mg/kg , i.d., remarkably inhibits the gastric secretion 6 hr after pylorus ligation. The aspirin-induced reductions of the total acid and K+ as well as the increments of the volume and Na+ in the gastric secretion are prevented dose-dependently by pretreatment with BTM-1086. The LD50 value by oral, s.c., and i.v. administration with this compound is 880, 630 and 113 mg/kg, respectively, for male rats and 830, 650 and 119 mg/kg, respectively, for female rats[2].
[1]. Eltze M, et al. Affinity profiles of BTM-1086 and BTM-1041 at muscarinic receptor subtypes and at H1- and alpha 1-receptors. Eur J Pharmacol. 1989 Nov 7;170(3):225-34. [2]. Hajimu Y, et al. Antiulcer Effect of (-)-cis-2, 3-Dihydro-3-(4-Methylpiperazinylmethyl)-2-Phenyl-1, 5-Benzothiazepin-4-(5H)-One Hydrochloride (BTM-1086) in Experimental Animals. Japan J Pharmacol. 41, 283-292 (1986).
| Animal experiment: | Rats[2]Rats weighing 180 to 190 g are anesthesized with ether and subjected to laparotomy to expose the stomach after which 20 gal of 20% acetic acid is injected carefully under the serous membrane of the abdominal side in the glandular stomach; then the abdomen is closed. Thereafter, the animals are fed normally and 5 mL/kg of BTM-1086 dissolved or suspended in 0.5% gum arabic solution is administered p.o. once daily for 14 days from the second day after the operation. The longitudinal and abscissal length of the areas are quickly measured with a calliper, and the multiplied product is used as the ulcer index[2]. | 
| References: [1]. Eltze M, et al. Affinity profiles of BTM-1086 and BTM-1041 at muscarinic receptor subtypes and at H1- and alpha 1-receptors. Eur J Pharmacol. 1989 Nov 7;170(3):225-34. | |
| Cas No. | 72293-17-5 | SDF | |
| Canonical SMILES | O=C1[C@H](CN2CCN(C)CC2)[C@H](C3=CC=CC=C3)SC4=CC=CC=C4N1 | ||
| 分子式 | C21H25N3OS | 分子量 | 367.51 | 
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C | 
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 | ||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
|  | 1 mg | 5 mg | 10 mg | 
| 1 mM | 2.721 mL | 13.6051 mL | 27.2101 mL | 
| 5 mM | 544.2 μL | 2.721 mL | 5.442 mL | 
| 10 mM | 272.1 μL | 1.3605 mL | 2.721 mL | 
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
			           2.
			一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
			           3. 以上所有助溶剂都可在 GlpBio 网站选购。
			
Quality Control & SDS
- View current batch:
- Purity: >98.00% 
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
 
 
   
   
   
  














